Literature DB >> 11790217

Oral antihyperglycemic therapy for type 2 diabetes: clinical applications.

Eric S Holmboe1.   

Abstract

Oral agents are the mainstay of pharmacologic treatment for type 2 diabetes, and physicians now have a number of agents to choose from. However, more choices translate into more complex decision making. Many patients with diabetes have associated comorbidities, and most diabetic patients will require more than 1 agent to achieve good glycemic control. This article illustrates several of the pharmacologic approaches to type 2 diabetes through 4 situations that use principles of evidence-based medicine. The scenarios also highlight some of the difficulties in choosing the optimal pharmacologic treatment regimen for individual patients. Physicians should also recognize that type 2 diabetes is a multisystem disorder that requires multidisciplinary care, including education and ongoing counseling for effective patient self-management of the disease. Finally, patient preferences are a vital component of informed decision making for pharmacologic treatment of diabetes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11790217     DOI: 10.1001/jama.287.3.373

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  8 in total

1.  Economic model of first-line drug strategies to achieve recommended glycaemic control in newly diagnosed type 2 diabetes mellitus.

Authors:  Joe W Ramsdell; Seth N Braunstein; Jennifer M Stephens; Christopher F Bell; Marc F Botteman; Scott T Devine
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

2.  Educating resident physicians using virtual case-based simulation improves diabetes management: a randomized controlled trial.

Authors:  JoAnn Sperl-Hillen; Patrick J O'Connor; Heidi L Ekstrom; William A Rush; Stephen E Asche; Omar D Fernandes; Deepika Appana; Gerald H Amundson; Paul E Johnson; Debra M Curran
Journal:  Acad Med       Date:  2014-12       Impact factor: 6.893

3.  Resource use among patients with diabetes, diabetic neuropathy, or diabetes with depression.

Authors:  Trong K Le; Stephen L Able; Maureen J Lage
Journal:  Cost Eff Resour Alloc       Date:  2006-10-23

4.  OATP1B3 (699G>A) and CYP2C9*2, *3 significantly influenced the transport and metabolism of glibenclamide and glipizide.

Authors:  Fayou Yang; Linlin Liu; Lin Chen; Mingyi Liu; Fanglan Liu; Yuqing Xiong; Xiao Hu; Chunhua Xia
Journal:  Sci Rep       Date:  2018-12-24       Impact factor: 4.379

5.  Stem cells from human exfoliated deciduous teeth ameliorate type II diabetic mellitus in Goto-Kakizaki rats.

Authors:  Nanquan Rao; Xiaotong Wang; Yue Zhai; Jingzhi Li; Jing Xie; Yuming Zhao; Lihong Ge
Journal:  Diabetol Metab Syndr       Date:  2019-02-28       Impact factor: 3.320

6.  Factors associated with results and conclusions of trials of thiazolidinediones.

Authors:  Gail Rattinger; Lisa Bero
Journal:  PLoS One       Date:  2009-06-08       Impact factor: 3.240

7.  CYP2C9 and OATP1B1 genetic polymorphisms affect the metabolism and transport of glimepiride and gliclazide.

Authors:  Fayou Yang; Xiaomin Xiong; Yonghua Liu; Hong Zhang; Shibo Huang; Yuqing Xiong; Xiao Hu; Chunhua Xia
Journal:  Sci Rep       Date:  2018-07-20       Impact factor: 4.379

8.  Bone Marrow-Derived Mesenchymal Stem Cells Restored High-Fat-Fed Induced Hyperinsulinemia in Rats at Early Stage of Type 2 Diabetes Mellitus.

Authors:  Gongchi Li; Han Peng; Shen Qian; Xinhua Zou; Ye Du; Zhi Wang; Lijun Zou; Zibo Feng; Jing Zhang; Youpeng Zhu; Huamin Liang; Binghui Li
Journal:  Cell Transplant       Date:  2020 Jan-Dec       Impact factor: 4.064

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.